spacer
home > ict > spring 2017 > turn of phrase
PUBLICATIONS
International Clinical Trials

Turn of Phrase

Over the past 10 years, the market value of the global pharmaceutical industry has more than doubled to $951 billion. In 2015, markets outside the US and Western Europe accounted for $362 billion, comprising approximately 38% of the total worldwide value (1).

There is no doubt about it: the healthcare industry has become truly global, and clinical trials are being delocalised to match. In fact, between 2005 and 2012, the largest annual growth in clinical trials occurred in Asian (30%) and Latin American/Caribbean (12%) regions (2).

As the clinical trials industry expands into emerging countries, protocols developed in one country are increasingly implemented in culturally and linguistically different locations. Competent and compliant translation is, therefore, becoming more necessary than ever in order to ensure that clinical trial protocols (CPTs) are correctly followed, and that participants can confidently understand and consent to them.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Alicia Lewis is a Brighton-based Writer and Content Specialist for full-service clinical trials agency MD Group. On the company’s website, she comments on the latest biotechnological innovations and creates guides to patientcentric clinical trial protocols. Since 2014, Alicia has been writing content for businesses in the UK and abroad, specialising in healthcare, business, travel and culture.
spacer
Alicia Lewis
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

BBI Solutions broadens antibody portfolio and strengthens reagent technical support capabilities with acquisition of Maine Biotechnology Services

BBI, a leading manufacturer of raw materials and finished test platforms, already provides human antigens, antibodies, serum and plasma products and clinical chemistry enzymes, for the in-vitro diagnostics market. Now with the acquisition of MBS they have strengthened their antibody offering, providing a comprehensive portfolio and custom services to deliver a total reagent solution for any immunoassay development.
More info >>

White Papers

Finding the Right End-to-End Safety Solution for Your Needs

Bioclinica

With upcoming changes, including the implementation of the International Conference on Harmonisation (ICH) E2B(R3) Electronic Transmission of Individual Case Safety Report and Identification of Medicinal Products (IDMP) standards, the current state of safety reporting can be confusing. Your existing safety system may not be flexible enough to accommodate these changing regulations, which are still moving targets regarding the details needed for a comprehensive solution with the right level of processes, company-to-company integrations and finalized regional rules.
More info >>

 
Industry Events

BioTrinity 2018

23-25 April 2018, Novotel London West in Hammersmith

BioTrinity 2018 is taking place from 23-25 April at the Novotel London West in Hammersmith. Now in its 12th year, BioTrinity remains the leading life sciences biopartnering and investment conference in Europe, and is a must attend event for R&D companies, TTO’s and academia who are looking to meet, collaborate, partner and seek funding from Big Pharma, Investors and Associated Industry companies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement